Health and Healthcare
Genocea Breaks Out With Very Positive Mid-Stage Results
Published:
Last Updated:
Genocea Biosciences Inc. (NASDAQ: GNCA) soared early on Thursday, following the release of positive data from its mid-stage genital herpes clinical trial. The company announced positive 12-month efficacy data from its Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.
The company believes that these results highlight the potential of GEN-003 to significantly enhance the genital herpes treatment landscape. Also considering the physical and psychological impact of this disease, both patients and treating physicians would be eager to use an effective treatment that more conveniently improves control of outbreaks.
GEN-003 demonstrated sustained and statistically significant reductions compared to baseline in the rate of viral shedding 12 months after dosing across multiple dose groups as well as sustained efficacy at multiple dose levels across secondary endpoints measuring the impact on clinical disease.
Ultimately the treatment was safe and well tolerated by patients, with no serious adverse events related to the vaccine in the trial.
24/7 Wall St.Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
